市場調查報告書
商品編碼
1402534
2030 年亞太地區眼藥水市場預測 - 區域分析 - 按類型(抗生素、人工淚液、荷爾蒙等)、應用和購買模式(非處方藥和處方藥)Asia Pacific Eye Drops Market Forecast to 2030 - Regional Analysis - by Type (Antibiotics, Artificial Tears, Hormones, and Others), Application, and Purchase Mode (OTC and Prescription) |
亞太地區眼藥水市場預計將從2022年的28.2384億美元成長到2030年的43.8659億美元。預計2022年至2030年CAGR為5.7%。
不斷湧現的眼部護理措施推動亞太眼藥水市場
近年來,人們採取了各種措施和努力來提高人們對眼部疾病的認知和教育,促使患者獲得合適的藥物和治療。
Sightsavers 是一個國際非政府組織,致力於在發展中國家治療和預防眼部疾病。印度大量人口居住在農村地區,對眼病的認知有限或根本沒有。 Sightsavers 旨在透過其農村眼健康計劃提高人們的意識,提供高品質的眼部健康服務,並消除農村人口中可避免的失明。此外,世衛組織於2019年啟動了全民健康覆蓋和眼保健:促進國家行動,旨在提供實用的分步指導,支持世衛組織會員國規劃和實施世衛組織世界報告的建議關於視力。世界衛生組織發起此活動的目的是提供以人為本的綜合眼科保健服務。此外,2020 年印美合作視覺研究計畫的重點是推進對於理解、預防和治療致盲眼症、視力障礙及相關併發症至關重要的科學和技術。印度生物技術部和美國 NEI 資助了該研究計畫。
2021 年 12 月,NIH 資助的計畫支持家樂氏眼科中心和阿拉文眼科醫院(印度)之間的合作夥伴關係,為眼保健專家開發臨床研究培訓計畫。此類培訓計劃旨在發展印度的眼保健領域。因此,增加眼保健研究資金可能為眼藥水市場參與者提供成長機會。
亞太地區眼藥水市場概況
亞太地區眼藥水市場細分為中國、日本、印度、澳洲、韓國和亞太地區其他地區。預計亞太地區在預測期內複合CAGR最快。亞太地區市場的成長歸因於澳洲和印度等國家乾眼症的日益普及。此外,老年人口的成長、醫療保健基礎設施的發展以及為促進研究活動而增加的投資預計將在預測期內推動亞太地區眼藥水市場的發展。在中國,每年約有20-30%的人被診斷出有乾眼症。導致乾眼症的主要因素包括長時間坐在電腦、筆記型電腦和手機前。此外,高空氣污染程度是該國乾眼症的另一個主要原因。該國是亞太地區糖尿病和青光眼發病率最高的國家,這可能會導致乾眼症。中國也是原料藥生產和學名藥的最大市場。該國多家公司參與眼科產品的生產。 2023年4月,Ocumension Therapeutics提交新藥申請(NDA),批准Zerviate 0.24%(西替利嗪)滴眼液在中國商業化。此溶液主要用於減少與過敏性結膜炎相關的眼部搔癢。
中國的亞太眼藥水市場競爭相當激烈,國內外藥廠都有駐足。該國的一些知名國產眼藥水品牌包括參天、諾華、愛爾康、艾爾建和博士倫,它們提供一系列眼部護理產品,包括處方眼藥水和非處方眼藥水 (OTC)解決方案。中國眼藥水的通路包括醫院、診所、藥局和電商平台。醫院和診所通常是提供處方眼藥水的公司首選的經銷商,而非處方眼藥水則可以在藥房和線上平台上輕鬆買到。
亞太地區眼藥水市場收入及 2030 年預測(百萬美元)
亞太地區眼藥水市場區隔
亞太地區眼藥水市場按類型、應用、購買模式和國家細分。
根據類型,亞太地區眼藥水市場分為抗生素、人工淚液、荷爾蒙等。 2022年,抗生素細分市場在亞太地區眼藥水市場中佔據最大佔有率。
根據應用,亞太地區眼藥水市場分為眼疾、眼部保健等。 2022年,眼疾細分市場在亞太眼藥水市場中佔據最大佔有率。眼疾細分市場進一步細分為乾眼症、青光眼、白內障等。
根據購買模式,亞太地區眼藥水市場分為非處方藥和處方藥。 2022 年,處方藥細分市場在亞太地區眼藥水市場中佔有更大佔有率。
依國家分類,亞太地區眼藥水市場分為中國、日本、印度、澳洲、韓國和亞太地區其他地區。 2022年,中國主導亞太地區眼藥水市場。
艾伯維公司、愛爾康公司、博士倫公司、Biomedica Pvt Ltd、輝瑞公司、Prestige Consumer Healthcare Inc.和樂敦製藥有限公司是亞太眼藥水市場上的一些領先公司。
The Asia Pacific eye drops market is expected to grow from US$ 2,823.84 million in 2022 to US$ 4,386.59 million by 2030. It is estimated to grow at a CAGR of 5.7% from 2022 to 2030.
Rising Initiatives for Eye Care Fuels Asia Pacific Eye Drops Market
In recent years, various measures and efforts have been taken to create awareness and educate people regarding eye diseases, prompting patients to access suitable medications and treatments.
Sightsavers-an international nongovernmental organization-works in developing countries to treat and prevent eye diseases. A large population in India resides in rural areas with limited or no awareness of eye ailments. Sightsavers aims to create awareness with its Rural Eye Health Programme, provide high-quality eye health services, and eradicate avoidable blindness in the rural population. In addition, in 2019, the WHO launched the Universal Health Coverage and Eye Care: Promoting Country Action, an event to provide practical, step-by-step guidance to support Member States of WHO in planning and implementing the recommendations of the WHO's World Report on vision. The WHO launched this event to provide integrated people-centered eye care services. Further, the India-US Collaborative Vision Research Program 2020 focuses on advancing science and technology crucial to understand, prevent, and treat blinding eye diseases, visual disorders, and associated complications. The Indian Department of Biotechnology and the US NEI fund this research program.
In December 2021, NIH-funded projects supported the partnership between Kellogg Eye Center and Aravind Eye Hospital (India) to develop a clinical research training program for eyecare specialists. Such training programs are meant to develop the eyecare field in India. Thus, increasing funds for eyecare research will likely offer growth opportunities to the eye drop market players.
Asia Pacific Eye Drops Market Overview
The Asia Pacific eye drops market is sub segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The growth of the market in Asia Pacific is attributed to the growing prevalence of dry eye diseases in countries such as Australia, and India. Additionally, the growing geriatric population, developing healthcare infrastructure, and increasing investments to boost research activities are projected to drive the Asia Pacific eye drops market during the forecast period. In China, every year about 20-30% of people are diagnosed with dry eye conditions. Major factors causing dry eye condition include long spending hours in front of computers, laptops, and mobile phones. Moreover, high air pollution level is another leading cause of dry eye condition in the country. The country records the highest incidences of diabetes and glaucoma in Asia Pacific, which may lead to a dry eye condition. China is also the largest market for API manufacturing and generic pharmaceuticals. Various companies in the country are involved in the production of ophthalmic products. In April 2023, Ocumension Therapeutics submitted a new drug application (NDA) for approval to commercialize Zerviate 0.24% (cetirizine) ophthalmic solution in China. This solution is majorly used to reduce ocular itching associated with allergic conjunctivitis.
The Asia Pacific eye drops market in China is quite competitive, with the presence of both domestic and international pharmaceutical companies. A few of the well-known domestic eye drop brands in the country are Santen, Novartis, Alcon, Allergan, and Baush + Lomb, which offer a range of eye care products, including prescription-based eye drops and over the counter (OTC) solutions. The distribution channels for eye drops in China include hospitals, clinics, pharmacies, and e-commerce platforms. Hospitals and clinics are commonly preferred as distributors by companies offering prescription-based eye drops, while OTC eye drops are readily available in pharmacies and online platforms.
Asia Pacific Eye Drops Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Eye Drops Market Segmentation
The Asia Pacific eye drops market is segmented into type, application, purchase mode, and country.
Based on type, the Asia Pacific eye drops market is segmented into antibiotics, artificial tears, hormones, and others. The antibiotics segment held the largest share of the Asia Pacific eye drops market in 2022.
Based on application, the Asia Pacific eye drops market is segmented into eye diseases, eye care, and others. The eye diseases segment held the largest share of the Asia Pacific eye drops market in 2022. The eye diseases segment is further segmented into dry eye, glaucoma, cataract, and others.
Based on purchase mode, the Asia Pacific eye drops market is segmented into OTC and prescription. The prescription segment held a larger share of the Asia Pacific eye drops market in 2022.
Based on country, the Asia Pacific eye drops market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific eye drops market in 2022.
AbbVie Inc, Alcon AG, Bausch & Lomb Inc, Biomedica Pvt Ltd, Pfizer Inc, Prestige Consumer Healthcare Inc., and Rohto Pharmaceutical Co Ltd are some of the leading companies operating in the Asia Pacific eye drops market.